Stocks Health care IMRX
NASDAQ · Health careImmuneering Corp (IMRX)
It posted a net loss of $66.5M. In fiscal 2025 capital spending exceeded operating cash flow by $45.5M. At September 30, 2026 it held $58.2M in cash. Its latest periodic report to the SEC is the quarterly report (10-Q) filed on October 29, 2026.
Key facts about Immuneering Corp
- Net worth
- Immuneering Corp has a market value (market cap) of $245.5M at the latest share price, and shareholders' equity of $168.7M on its balance sheet at September 30, 2026. A company's "net worth" usually means one of these: what the market pays for all its shares, or its assets minus its liabilities.
- Revenue and profit
- In fiscal 2023 revenue was $0 (-100.0% year on year), with a net loss of $53.5M.
- Cash flow
- In fiscal 2025 operations used $45.3M of cash.
- Latest report
- The latest periodic report (quarterly report, 10-Q) was filed with the SEC on October 29, 2026 and covers the period to September 30, 2026. Open on SEC EDGAR
- Next earnings report
- Immuneering Corp's next report is expected around March 5, 2027. That is an estimate from its filing rhythm, not a date the company has announced.
What Immuneering Corp does
Immuneering Corp is registered with the SEC under industry code SIC 2834 (Pharmaceutical Preparations). Its shares trade on NASDAQ under the ticker IMRX.
Revenue and profit by year
Key figures
| Fiscal year | Revenue | Net income | Diluted EPS | Free cash flow |
|---|---|---|---|---|
| 2025 | n/a | -$56M | -$1.27 | -$45.5M |
| 2024 | n/a | -$61M | -$2.04 | -$55.1M |
| 2023 | $0 | -$53.5M | -$1.88 | -$49.3M |
| 2022 | $317K | -$50.5M | -$1.91 | -$44.8M |
| 2021 | $2.1M | -$33.5M | -$2.46 | -$30.9M |
| 2021 | $2.3M | -$17M | -$3.44 | -$14.7M |
Earnings: every quarter and the next report date
Full financial statements: income, balance sheet and cash flow
Latest SEC filings
What Immuneering Corp has filed recently, newest first. Each links to the original document on SEC EDGAR.
- November 9, 2026
- October 29, 2026
- October 29, 2026
- August 5, 2026
- August 5, 2026
- July 28, 2026Passive stake (5% or more) SCHEDULE 13G
- June 15, 2026
- June 11, 2026
- June 1, 2026Other event 8-K
- May 15, 2026
Insider trades
What the people running Immuneering Corp did with its shares, from the Form 4 filings they must send the SEC within two business days.
No insider trades were reported in the last 90 days.
| Date | Insider | What | Shares | Value |
|---|---|---|---|---|
| June 23, 2026 | Zeskind Benjamin J.PRESIDENT AND CEO, Director | Bought | 2,400 | $10.9K |
| June 15, 2026 | Hall Brett MatthewCHIEF SCIENTIFIC OFFICER | Bought | 6,035 | $25K |
| March 13, 2026 | Neufeld Leah RCHIEF PEOPLE OFFICER | Received as pay | 3,628 | $15.6K |
| January 16, 2026 | Brakewood Harold EugeneChief Business Officer | Bought | 5,250 | $25K |
| January 15, 2026 | Schall Thomas J.Director | Bought | 21,645 | $101K |
| January 15, 2026 | Hall Brett MatthewCHIEF SCIENTIFIC OFFICER | Bought | 2,298 | $10.5K |
| January 13, 2026 | Neufeld Leah RCHIEF PEOPLE OFFICER | Bought | 2,626 | $10.9K |
| January 12, 2026 | Feinberg PeterDirector | Boughtindirect | 20,000 | $86.9K |
Who owns IMRX
Three views from three kinds of SEC filings, each with its own date. They overlap and are not added up.
5% holders
| Holder | Of class | Filed |
|---|---|---|
| Fmr LLC13G, passive with 1 related filers | 14.5% | October 7, 2025 |
| HBM Healthcare Investments (Cayman) Ltd.13G, passive | 5.7% | October 3, 2025 |
Largest institutional holders
Insiders
6 insiders reported holding 2,948,402 shares in total, about $11.2M at the last price.
| Holder | Shares |
|---|---|
| Zeskind Benjamin J.PRESIDENT AND CEO, Director | 2,315,252 |
| Hall Brett MatthewCHIEF SCIENTIFIC OFFICER | 382,531 |
| Feinberg PeterDirector | 135,441135,441 held indirectly |
| Schall Thomas J.Director | 74,530 |
| Neufeld Leah RCHIEF PEOPLE OFFICER | 29,598 |
| Brakewood Harold EugeneChief Business Officer | 11,050 |
Questions about IMRX
What does Immuneering Corp do?
Immuneering Corp is a company in the Health care sector, listed on NASDAQ as IMRX. Its shares trade on NASDAQ under the ticker IMRX.
What is Immuneering Corp's net worth?
Immuneering Corp has a market value (market cap) of $245.5M at the latest share price, and shareholders' equity of $168.7M on its balance sheet at September 30, 2026. A company's "net worth" usually means one of these: what the market pays for all its shares, or its assets minus its liabilities.
Is Immuneering Corp profitable?
No. Over the twelve months to September 30, 2026 it reported a net loss of $66.5M.
When did Immuneering Corp last report?
Its most recent periodic report is the quarterly report (10-Q) filed on October 29, 2026. It covers the period to September 30, 2026. Its newest filing of any kind is the executive or director change from November 9, 2026.
When is Immuneering Corp's next earnings report?
Immuneering Corp's next report is expected around March 5, 2027. That is an estimate from its filing rhythm, not a date the company has announced.
Similar companies
Compare IMRX with
Follow IMRX
Get an email when Immuneering Corp files with the SEC: results, executive changes, material agreements and annual reports.
Where the numbers come from
Financial figures are the values Immuneering Corp tagged in its own SEC filings (XBRL), taken from the latest filing for each period, so restatements replace older figures. Revenue, profit and cash flow are for full fiscal years unless marked as the last twelve months, which is the sum of the four most recent quarters. Where a company reports only the full year, the fourth quarter is the year minus the first three.
Prices are delayed end-of-day market data in the listing currency, and market cap moves with the price. P/E is shown only when earnings per share are positive. Nothing here is investment advice.